Regenerative Therapies

Peptides

Sermorelin:

• Is a growth hormone releasing hormone (GHRH) truncated analog
• Works just like endogenous GHRH. It binds to pituitary GHRH receptors and stimulates pulsatile growth hormone (GH) release.
• Half-life: 10-20 minutes, GH stays elevated for ~ 2 hours
• It is effective for the following:
  • Wound healing
  • Improved energy
  • Muscle strength, maintenance, and growth Improved fat burning
  • Improved sleep quality

CJC-1295:

• A growth hormone releasing hormone analog (GHRH)
• Long half-life: 5.8-8.1 days, elevated GH and IGF-1 for 10-13 days
• It will stimulate pituitary endogenous GH release and will increases endogenous IGF-1.
• Benefits:
  • Improved physical performance and recovery.
  • Increased muscle mass
  • Improved weight loss and fat burning
  • Improved bone mineral density (BMD)
  • Neuroprotective
  • Enhanced sex drive

Ipamorelin:

• Is a synthetic pentapeptide that is a selective agonist of ghrelin growth hormone secretagogue receptor pathway, half-life: 1.5-2.0 hours.
• Ghrelin is the hunger hormone.
  It stimulates pituitary growth hormone (GH) release.
• Benefits:
  • Improved gastric motility.
  • Improved Gl recovery after bowel resection (human)
  • Increased collagen production and wrinkle reduction
  • Promotes an increase in lean muscle mass, muscle growth,
    and exercise recovery time.
  • Supports increased metabolic rate and fat loss.
  • Improves sleep.
  • Promotes bone health and bone strength along with increased energy, immune health.

NOTE: CJC-1295 and Ipamorelin have SYNERGISTIC benefits.

• Improved weight loss and muscle mass maintenance
• Deep wave sleep

CJC-1295 and Ipamorelin SHOULD NOT be used in the following individuals:

• Professional athletes, competitive athletes, cancer patients, patients at high risk for cancer
• Caution in patients with potential thyroid issues, as GH may mask
  hypothyroid symptoms.
• Common Side Effects
  • CJC-1295/Ipamorelin reported safe in recommended doses.
  • Flushing, redness at injection site, rash, edema, joint and muscle pain, fatigue

BPC-157:

• It is a stable gastric pentadecapeptide 15 amino acids.
• Use orally for conditions such as ulcerative colitis and Crohn's disease.
• Non-human studies document clinical efficacy in oral, subcutaneous (SQ), or intramuscular (IM) dosing
• Can be administered IM close to an injured site thereby promoting increased blood flow to the area of injury promoting increased cell
  survival.
• Can be administered SQ for systemic effects.
• Can be administered orally for gut and systemic effects.
• It will support a decrease in inflammation and an increase in nitrous oxide.
• It will support healing of many different tissue types including tendon, muscle, nervous system, and damaged ligaments.
• May protect organs, prevent stomach ulcers, and heal skin burns, chemical burns, cornea injuries, gastric ulcers, and inflammatory
  diseases.
• We do not recommend in clients w/CANCER.
• Common Side Effects: Injection site reactions
• Rare Side Effects: erythema, transient muscle atrophy, polyarthralgia with hand edema, and rash

MOTS-C:

• Is a mitochondrial-derived peptide that has metabolic signaling
  activity with potent anti-obesity effects.
• MOTS-c levels decline with age.
• It supports a decrease in inflammation and oxidative stress.
• It supports mitochondrial energy production from glucose.
• It increases glucose utilization, especially in skeletal muscle.
• In animal and human studies, it may support beneficial effects on age-related diseases including:
  • Diabetes Mellitus (DM), cardiovascular disease (CVD), osteoporosis, obesity, and cognitive decline

KPV:

• KPV is an endogenous tridecapeptide 3 amino acid sequence (Lys-Pro-Val) based on the C-terminal alpha-MSH sequence.
• Non-human studies document therapeutic and clinical efficacy in oral, SQ, or IM dosing
• Benefits:
  • Potent anti-inflammatory effects against the following:
    • Allergic and irritant dermatitis
    • Cutaneous vasculitis
    • Asthma
    • Rheumatoid arthritis flare-ups
    • Colitis-induced colon cancer tumorigenesis
  • Supports immune modulation in non-human studies.
  • Supports gut health in animal models.
  • Decreases colon inflammation in particular colitis flares (after oral administration)
  • Human studies support use of topically applied KPV cream for nickel-induced contact dermatitis
  • Antimicrobial effects documented in in-vitro studies.
  • Highly effective against resistant Candida albicans and Staphylococcus aureus
• Not recommended for clients with CANCER.
• No reported side effects.

GHK-Cu:

• GHK-Cu is a peptide (a short chain of amino acids) made up of three amino acids: glycine, histidine, and lysine, hence GHK. Because GHK bonds easily to copper, we refer to it has GHK-Cu.
• GHK-Cu is produced naturally in our bodies and is found in blood, saliva, and urine.  It has a role in repairing DNA leading to improved tissue growth. When we age, the genes that are involved in inflammation and tissue destruction become more active while
  the genes that regenerate and repair tissue become less active.
• GHK-Cu appears to help turn back the clock by reactivating the regenerative genes and deactivating the inflammatory and
  destructive ones.
• GHK-Cu has also been linked to several other processes that support tissue creation and has been found to have additional
  benefits:
  • Stimulates synthesis of collagen in skin cells
  • Increases the accumulation of protein.
  • Increases the synthesis of decorin and metalloproteinases as well as inflammatory cytokine interleukin 6.
  • Serves as a potent stimulant of antioxidant gene activity.
  • Reduces pain, anxiety, and aggression.
  • Improves wound and skin healing and promotes tissue remodeling.
  • Improves hair growth.
  • Reduces wrinkles and is anti-aging.
    • It has been well-studied as an anti-aging agent and is considered to be an activator of tissue remodeling.
    • In one study involving women with sun-damaged skin, GHK-Cu treatment removed visible signs of aging after 12-weeks. It improved skin firmness, elasticity, and
      clarity as well as reduced wrinkles and fine lines.
    • It also has been shown to tighten skin; improve elasticity and firmness; improve skin density; reduce hyperpigmentation and sun damage.
• Based on available research, GHK-Cu is considered to be safe and well-tolerated. The lowest known doses of GHK-Cu administered to test subjects involve the application of skin creams and topical ointments. Skin creams containing GHK-Cu are usually applied
  once or twice a day to affected areas—usually to the face for skin tightening and wrinkles, to the scalp for hair growth, or other areas for scars or wound healing. When administered in this manner, GHK-Cu appears to be non-toxic and non-irritating with no adverse effects.
• When injected, there is little data to indicate the minimum effective dose of GHK-Cu.

PT-141:

• PT-141 (bremelanotide) is an FDA-approved treatment of low sexual desire in women and is also known to treat sexual arousal disorder in men.
• PT-141 is an agonist of the melanocortin receptors, with high affinity for MC4R, the stimulation of which increases sexual desire
  and causes sexual arousal in both men and women.
• In 2019, bremelanotide (PT-141) was approved in the United States as a therapy for premenopausal women with hypoactive
  sexual desire disorder (HSDD), and it is currently available under the brandname Vyleesi in auto-injection pens.
• In addition to its role in treating HSDD in women, PT-141 has been extensively studied in a variety of contexts, including for its roles in treating erectile dysfunction (ED) and other forms of sexual dysfunction.  Following a subcutaneous injection of PT-141, maximal levels occur after about one hour, with a range of 30 minutes to one hour. In the realm of male sexual desire, this translates to a virtually on-demand erection.
• While PT-141 is not indicated to treat erectile dysfunction (ED), several small-scale studies have found that it may be beneficial to
  male patients with ED who do not respond to sildenafil (Viagra).
• A 2004 study involving fewer than 400 patients found that doses of 1mg of PT-141(bremelanotide) could produce a statistically significant “erectile response”.
• Based on the above results, the safety and efficacy of PT-141 in test subjects with mild to moderate ED were investigated in a phase II study. Results showed a 3-fold increase in erectile activity following 20mg intranasal administration of PT-141.
• A 2008 study involving intranasal bremelanotide spray found that it could help men achieve an erection suitable for penetrative sex when administered 45 minutes prior to intercourse.
• These findings suggest that PT-141 may act as an alternative ED treatment for subjects who do not respond to sildenafil (Viagra).
• At the recommended dose of 1.75 mg, bremelanotide may produce the following common side effects:
  • Nausea (40% particularly with the first injection)
  • Flushing (20%)
  • Injection site reactions (13%)
  • Headaches (11%)
• Uncommon adverse reactions include:
  • Increases in blood pressure.
  • Severe nausea
  • Vomiting
  • Arthralgia
  • Restless leg syndrome
  • Local hyperpigmentation
• Due to the risk of the peptide causing an increase in blood pressure and reduction in heart rate, it should not be administered to subjects who are:
  • Pregnant or suspected of being pregnant.
  • Suffering from cardiovascular disease
  • Diagnosed with uncontrolled hypertension.
• In rare instances, PT-141 may lead to elevated serum enzyme levels, and in even rarer cases, cause acute liver damage.